{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:56:54Z","timestamp":1769633814667,"version":"3.49.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We describe <jats:sup>68<\/jats:sup>Ga-FAPI (fibroblast activation protein inhibitor)-04 and <jats:sup>18<\/jats:sup>F-FDG PET\/CT findings in a case with epithelioid malignant pleural mesothelioma. Compared with <jats:sup>18<\/jats:sup>F-FDG PET\/CT, <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT more clearly showed the pleural tumors and lymph node metastases and detected more pleural lesions because the tumors showed higher <jats:sup>68<\/jats:sup>Ga-FAPI-04 activity. This case indicates that <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT may be a promising new tool in evaluation of malignant pleural mesothelioma, which needs further investigation.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004269","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:09:21Z","timestamp":1665425361000},"page":"980-981","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["68Ga-FAPI-04 Versus 18F-FDG PET\/CT in Detection of Epithelioid Malignant Pleural Mesothelioma"],"prefix":"10.1097","volume":"47","author":[{"given":"Aisheng","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjing","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11604-016-0555-1","article-title":"Present and future roles of FDG-PET\/CT imaging in the management of malignant pleural mesothelioma","volume":"34","year":"2016","journal-title":"Jpn J Radiol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2012.10.017","article-title":"18F-fluoro-2-deoxy-d-glucose positron emission tomography\/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough","volume":"79","year":"2013","journal-title":"Lung Cancer"},{"key":"bib3-20250621","first-page":"e17263","article-title":"False-negative 18F-fluorodeoxyglucose PET\/CT in malignant pleural mesothelioma","volume":"13","year":"2021","journal-title":"Cureus"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/JTO.0b013e3182519d96","article-title":"High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology","volume":"7","year":"2012","journal-title":"J Thorac Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib6-20250621","article-title":"Correlation of 68Ga-FAPI-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study [published online November 5, 2021]","year":"2021","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.121.262096","article-title":"68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"11192","DOI":"10.3390\/ijms222011192","article-title":"Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F]F-FDG in oncology: a systematic review","volume":"22","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","article-title":"68Ga-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma","volume":"47","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:03:38Z","timestamp":1750536218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004269","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}